Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors

SIMPLE SUMMARY: Drug resistance is a major issue in brain tumor therapy. Despite novel promising therapeutic approaches, glioblastoma (GBM) remains refractory in showing beneficial responses to anticancer agents, as demonstrated by the failure in clinical trials of small kinase inhibitors. One of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabro, Federica, Lamfers, Martine L. M., Leenstra, Sieger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833415/
https://www.ncbi.nlm.nih.gov/pubmed/35158868
http://dx.doi.org/10.3390/cancers14030600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833415/
https://www.ncbi.nlm.nih.gov/pubmed/35158868
http://dx.doi.org/10.3390/cancers14030600

Ejemplares similares